Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema

← catalyst calendar

NCT07592273 · readout ≤ 680 d

Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.

Phase

Phase 2/3

Status

Recruiting

Study type

Interventional

Design

Randomized · Double · Treatment

Enrollment

576estimated

Sites

Countries

Puerto Rico, United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-06-01

actual

When the study began enrolling

Primary completion

Jun 2028

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Jan 2036

estimated

The whole study's end, after follow-up

First posted

2026-05-18

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-14

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Diabetic Retinopathy

Interventions

Drug: Surabgene Lomparvovec
Drug: Sham
Drug: Topical Steroid
Drug: Artificial Tears

Primary outcomes

what the primary-completion date above is the date OF

Phase 2B: Percentage of Participants Achieving >= 2-Step Improvement from Baseline in Diabetic Retinopathy Severity Scale (DRSS) in the Study Eye

measured At Week 52

Phase 3: Percentage of Participants Achieving >= 2-Step Improvement from Baseline in Diabetic Retinopathy Severity Scale (DRSS) in the Study Eye

measured At Week 52

Bilateral Portion: Bilateral portion: Number of participants experiencing ocular Adverse Events (AEs), Serious Adverse Events (SAEs), or any Adverse Events of Special Interest (AESIs)

measured Up to Approximately Week 104

Bilateral Portion: Participants Who Experience Intraocular Inflammation

measured Up to Approximately Week 104

Bilateral Portion: Participants Who Experience Scleral Inflammation Including Episcleritis

measured Up to Approximately Week 104

Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed